Podcast
MSL Talk: Tom Caravela, Giovanni Passiatore
3 Things I wish I knew about being a MSL
Summary
In this episode, Tom Caravela welcomes Mitchell D’Rozario from Genentech Roche to share his journey into the MSL role. Mitchell provides three key insights he wishes he had known before becoming an MSL and poses thought-provoking questions to Tom. The discussion covers staying motivated and purpose-driven, exploring alternative career paths in the pharmaceutical industry, and the challenges of building relationships in a virtual environment. They also delve into the changing landscape of conferences and the importance of face-to-face interactions. The episode concludes with closing remarks, gratitude, and a request for subscription and feedback.
My guest today is Mitchell D’Rozario, Medical Science Liaison at Genentech and we discuss the 3 things he wished he knew about being an MSL.
In this episode we discuss:
- Mitchell’s background and breaking into the industry
- 3 things he wishes he had known about being an MSL
- What Tom wishes aspiring MSLs knew about the role
- What Tom looks for when screening candidates for roles
- Some red flags Tom notices often
- What keeps Mitchell on track
- What Mitchell learned in 2020 going through pandemic and how it changed him as an MSL
- His opinion of what 2021 will look like for field medical and what MSLs might expect
MSL career insights, pharmaceutical industry careers, virtual relationship building, Medical Science Liaison challenges, conference networking importance
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Giovanni Passiatore
Article
Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
Article
Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
Article
Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
Article
iNIZIO
Transforming oncology: Five frontiers driving progress in cancer care
Article
iNIZIO